Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors

US8759532B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Jennifer R. Allen · Newbury Park, US
• Kaustav Biswas · Thousand Oaks, US
• Frank Chavez · San Diego, US
• Ning Chen · Thousand Oaks, US
• Frenel F. De Morin · Thousand Oaks, US
• James R. Falsey · Moorpark, US
• Michael J. Frohn · Thousand Oaks, US
• Paul E. Harrington · Camarillo, US
• Daniel Brian Home · Simi Valley, US
• Essa Hu Harrington · Camarillo, US
• Matthew R. Kaller · Ventura, US
• Roxanne Kunz · Santa Monica, US
• Holger Monenschein · San Diego, US
• Thomas Nguyen · Newbury Park, US
• Alexander J. Pickrell · Westlake Village, US
• Andreas Reichelt · Moorpark, US
• Shannon Rumfelt · Camarillo, US
• Robert M. Rzasa · Ventura, US
• Kelvin Sham · Thousand Oaks, US
• Guomin Yao · Mililani, US

Key dates

• Filing date: Nov 14, 2012
• Grant date: Jun 24, 2014
• Expiry date: Nov 14, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.